XML 42 R31.htm IDEA: XBRL DOCUMENT v3.19.2

Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Revenue	$ 52,019	$ 0
Astellas Agreement [Member] | Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	88,612
Deferred Revenue	136
Total Consideration	88,748
Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	14,523
Deferred Revenue	136
Total Consideration	14,659
Astellas Agreement [Member] | Japan [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	74,089
Deferred Revenue	0
Total Consideration	74,089
Astellas Agreement [Member] | Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	712,255
Deferred Revenue	2,019
Total Consideration	714,274
Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	224,304
Deferred Revenue	2,019
Total Consideration	226,323
Astellas Agreement [Member] | Europe [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	487,951
Deferred Revenue	0
Total Consideration	487,951
AstraZeneca Agreements [Member] | U.S./RoW and China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	778,677
Deferred Revenue	152,926
Total Consideration	931,603
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	327,275
Deferred Revenue	0
Total Consideration	327,275
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	451,402
Deferred Revenue	16,342
Total Consideration	467,744
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	0
Deferred Revenue	136,584
Total Consideration	$ 136,584

X

- Definition

The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.

+ References

No definition available.

+ Details

Name:	fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.

+ References

No definition available.

+ Details

Name:	fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: